4D Molecular Therapeutics Inc
FDMT
Company Profile
Business description
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Contact
5858 Horton Street
Suite 455
EmeryvilleCA94608
USAT: +1 510 505-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
227
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.90 | 39.90 | -0.44% |
| CAC 40 | 7,879.82 | 92.84 | 1.19% |
| DAX 40 | 23,646.12 | 286.94 | 1.23% |
| Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
| FTSE 100 | 9,225.79 | 17.42 | 0.19% |
| HKSE | 26,544.85 | 363.54 | -1.35% |
| NASDAQ | 22,261.33 | 72.63 | -0.33% |
| Nikkei 225 | 45,303.43 | 513.05 | 1.15% |
| NZX 50 Index | 13,120.03 | 108.35 | -0.82% |
| S&P 500 | 6,600.35 | 6.41 | -0.10% |
| S&P/ASX 200 | 8,745.20 | 47.70 | -0.54% |
| SSE Composite Index | 3,831.66 | 44.68 | -1.15% |